Miriam Potrony1, Joan Anton Puig-Butillé2, Paula Aguilera1, Celia Badenas2, Cristina Carrera1, Josep Malvehy1, Susana Puig3. 1. Centro de Investigación Biomédica en Red de Enfermedades Raras ISCIII, Barcelona, Spain; Dermatology Department, Melanoma Unit, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. 2. Centro de Investigación Biomédica en Red de Enfermedades Raras ISCIII, Barcelona, Spain; Biochemical and Molecular Genetics Service, Melanoma Unit, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. 3. Centro de Investigación Biomédica en Red de Enfermedades Raras ISCIII, Barcelona, Spain; Dermatology Department, Melanoma Unit, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Electronic address: susipuig@gmail.com.
Abstract
BACKGROUND: Cyclin-dependent kinase inhibitor 2A (CDKN2A) is the major high-risk susceptibility gene for melanoma. OBJECTIVE: We sought to evaluate the effect of CDKN2A mutations in Spanish patients with a high risk of developing melanoma and the association with clinical and family history features. METHODS: A cross-sectional study design was used to analyze the CDKN2A impact in 702 Spanish patients with a high risk of developing melanoma. RESULTS: The CDKN2A mutation prevalence was 8.5% in patients with sporadic multiple primary melanoma and 14.1% in familial melanoma. Number of cases in the family, number of primary melanomas, and age of onset were associated with the presence of CDKN2A mutation. Having a CDKN2A mutation in the family increased the prevalence of other cancers (prevalence ratio [PR] 2.99, P=.012) and prevalence of pancreatic (PR 2.97, P=.006), lung (PR 3.04, P<.001), and breast (PR 2.19, P=.018) cancers but not nephrourologic or colon cancer. LIMITATIONS: Smoking status was not assessed in the individuals with lung cancer. CONCLUSIONS: Melanoma-prone families with mutations in CDKN2A have an increased prevalence of a broad spectrum of cancers including lung, pancreatic, and breast cancer. This information should be included in genetic counseling and cancer prevention programs for CDKN2A mutation carriers.
BACKGROUND:Cyclin-dependent kinase inhibitor 2A (CDKN2A) is the major high-risk susceptibility gene for melanoma. OBJECTIVE: We sought to evaluate the effect of CDKN2A mutations in Spanish patients with a high risk of developing melanoma and the association with clinical and family history features. METHODS: A cross-sectional study design was used to analyze the CDKN2A impact in 702 Spanish patients with a high risk of developing melanoma. RESULTS: The CDKN2A mutation prevalence was 8.5% in patients with sporadic multiple primary melanoma and 14.1% in familial melanoma. Number of cases in the family, number of primary melanomas, and age of onset were associated with the presence of CDKN2A mutation. Having a CDKN2A mutation in the family increased the prevalence of other cancers (prevalence ratio [PR] 2.99, P=.012) and prevalence of pancreatic (PR 2.97, P=.006), lung (PR 3.04, P<.001), and breast (PR 2.19, P=.018) cancers but not nephrourologic or colon cancer. LIMITATIONS: Smoking status was not assessed in the individuals with lung cancer. CONCLUSIONS:Melanoma-prone families with mutations in CDKN2A have an increased prevalence of a broad spectrum of cancers including lung, pancreatic, and breast cancer. This information should be included in genetic counseling and cancer prevention programs for CDKN2A mutation carriers.
Authors: Sara Gandini; Francesco Sera; Maria Sofia Cattaruzza; Paolo Pasquini; Damiano Abeni; Peter Boyle; Carmelo Francesco Melchi Journal: Eur J Cancer Date: 2005-01 Impact factor: 9.162
Authors: P Ghiorzo; P Ciotti; M Mantelli; A Heouaine; P Queirolo; M L Rainero; C Ferrari; P L Santi; R De Marchi; A Farris; F Ajmar; P Bruzzi; G Bianchi-Scarrà Journal: Int J Cancer Date: 1999-11-12 Impact factor: 7.396
Authors: C J Hussussian; J P Struewing; A M Goldstein; P A Higgins; D S Ally; M D Sheahan; W H Clark; M A Tucker; N C Dracopoli Journal: Nat Genet Date: 1994-09 Impact factor: 38.330
Authors: S Puig; A Ruiz; T Castel; V Volpini; J Malvehy; F Cardellach; M Lynch; J M Mascaro; X Estivill Journal: Hum Genet Date: 1997-12 Impact factor: 4.132
Authors: N Soufir; M F Avril; A Chompret; F Demenais; J Bombled; A Spatz; D Stoppa-Lyonnet; J Bénard; B Bressac-de Paillerets Journal: Hum Mol Genet Date: 1998-02 Impact factor: 6.150
Authors: G J Walker; C J Hussussian; J F Flores; J M Glendening; F G Haluska; N C Dracopoli; N K Hayward; J W Fountain Journal: Hum Mol Genet Date: 1995-10 Impact factor: 6.150
Authors: Miriam Potrony; Celia Badenas; Paula Aguilera; Joan Anton Puig-Butille; Cristina Carrera; Josep Malvehy; Susana Puig Journal: Ann Transl Med Date: 2015-09
Authors: Morgan A Gingerich; Joshua D Smith; Nicole L Michmerhuizen; Megan Ludwig; Samantha Devenport; Chloe Matovina; Chad Brenner; Steven B Chinn Journal: Head Neck Date: 2018-02-10 Impact factor: 3.147
Authors: M Potrony; J A Puig-Butille; M Ribera-Sola; V Iyer; C D Robles-Espinoza; P Aguilera; C Carrera; J Malvehy; C Badenas; M T Landi; D J Adams; S Puig Journal: Br J Dermatol Date: 2019-02-27 Impact factor: 9.302
Authors: Nicholas J Taylor; Elizabeth A Handorf; Nandita Mitra; Marie-Françoise Avril; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarrà; D Timothy Bishop; Brigitte Bressac-de Paillerets; Donato Calista; Lisa A Cannon-Albright; Francisco Cuellar; Anne E Cust; Florence Demenais; David E Elder; Eitan Friedman; Anne-Marie Gerdes; Paola Ghiorzo; Alisa M Goldstein; Thais C Grazziotin; Johan Hansson; Nicholas K Hayward; Marko Hocevar; Veronica Höiom; Elizabeth A Holland; Christian Ingvar; Maria Teresa Landi; Gilles Landman; Alejandra Larre-Borges; Sancy A Leachman; Graham J Mann; Eduardo Nagore; Håkan Olsson; Jane Palmer; Barbara Perić; Dace Pjanova; Susana Puig; Helen Schmid; Nienke van der Stoep; Margaret A Tucker; Karin A W Wadt; Linda Whitaker; Xiaohong R Yang; Julia A Newton Bishop; Nelleke A Gruis; Peter A Kanetsky Journal: J Invest Dermatol Date: 2016-01-28 Impact factor: 8.551
Authors: C Longo; V Barquet; E Hernandez; A A Marghoob; M Potrony; C Carrera; P Aguilera; C Badenas; J Malvehy; S Puig Journal: J Eur Acad Dermatol Venereol Date: 2020-07-28 Impact factor: 9.228
Authors: Iván Márquez-Rodas; Manuel Martín González; Eduardo Nagore; Cristina Gómez-Fernández; Jose Antonio Avilés-Izquierdo; Cayetana Maldonado-Seral; Virtudes Soriano; Margarita Majem-Tarruella; Virginia Palomar; Rocio Maseda; Alfonso Martín-Carnicero; Teresa Puertolas; Elena Godoy; Pablo Cerezuela; Maria Ochoa de Olza; Begoña Campos; Elisabeth Perez-Ruiz; Ainara Soria; Irene Gil-Arnaiz; Maria Gonzalez-Cao; Elisa Galvez; Ana Arance; Joaquin Belon; Luis de la Cruz-Merino; Salvador Martín-Algarra Journal: PLoS One Date: 2015-04-13 Impact factor: 3.240